News
Company
Company

Select Year

NeuShen Therapeutics Announces NMPA-CDE Acceptance of IND Application for Highly Selective KCNQ2/3 Activator

2023.12.27

NeuShen Therapeutics Announces NMPA-CDE Acceptance of IND Application for Highly Selective KCNQ2/3 Activator

NeuShen Therapeutics-UMass Chan ALS Program to Present Pre-Clinical Data at ESGCT 2023

2023.10.24

NeuShen Therapeutics-UMass Chan ALS Program to Present Pre-Clinical Data at ESGCT 2023

NeuShen Therapeutics Hosted Special Event Featuring Top Gene Therapy and Clinical Psychiatry Experts

2023.10.20

NeuShen Therapeutics Hosted Special Event Featuring Top Gene Therapy and Clinical Psychiatry Experts

NeuShen Therapeutics Announces Poster Presentation of a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia at Neuroscience 2023

2023.09.27

NeuShen Therapeutics Announces Poster Presentation of a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia at Neuroscience 2023

NeuShen Therapeutics Announces Poster Presentation of Novel KCNQ2/3 Selective Activator NS-041 at ACS FALL 2023

2023.08.03

NeuShen Therapeutics Announces Poster Presentation of Novel KCNQ2/3 Selective Activator NS-041 at ACS FALL 2023

NeuShen Therapeutics Company Activities During 2023 BIO International Convention Week

2023.06.25

NeuShen Therapeutics Company Activities During 2023 BIO International Convention Week

NeuShen Therapeutics Announces License Agreement With Hangzhou HealZen Therapeutics

2023.04.20

NeuShen Therapeutics Announces License Agreement With Hangzhou HealZen Therapeutics

NeuShen Therapeutics Celebrates R&D Center Opening in Boston

2023.02.28

NeuShen Therapeutics Celebrates R&D Center Opening in Boston

NeuShen Therapeutics Funds ALS Research at UMass Chan Medical School

2023.01.28

NeuShen Therapeutics Funds ALS Research at UMass Chan Medical School

< 1 >